Abstract: Tissue replacement implants are disclosed that include polarized retinal pigment epithelial cells on a polylactic-co-glycolic acid) (PLGA) scaffold, wherein the PLGA scaffold is 20-30 microns in thickness, has a DL-lactide/glycotide ratio of about 1:1, an average pore size of less than about 1 micron, and a fiber diameter of about 150 to about 650 nm. Also disclosed are methods of treating a subject with a retinal degenerative disease, retinal or retinal pigment epithelium dysfunction, retinal degradation, retinal damage, or loss of retinal pigment epithelium. These methods include locally administering to the eye of the subject the tissue replacement implant. In further embodiments, methods are disclosed for producing the tissue replacement implant.
Type:
Application
Filed:
November 18, 2019
Publication date:
January 20, 2022
Applicant:
THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARMENT OF HEALTH AND HUMAN SERVICES
Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
December 25, 2012
Assignees:
The Ohio State University Research Foundation, The United States of America, as represented by the Secretary of the Deparment of Health and Human Services, National Institute of Health, Office of Technology Transfer
Inventors:
Carlo M. Croce, Curtis C. Harris, Aaron J. Schetter
Abstract: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.
Type:
Grant
Filed:
July 8, 2011
Date of Patent:
October 16, 2012
Assignee:
The United States of America, as represented by the Secretary, Deparment of Health and Human Services
Inventors:
Mark E. Dudley, Steven A. Rosenberg, John R. Wunderlich
Abstract: Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
Type:
Grant
Filed:
March 30, 2010
Date of Patent:
December 13, 2011
Assignees:
The United States of America as represented by the Secretary of the Deparment of Health and Human Services, The Trustees of the University of Pennsylvania
Inventors:
Daniel H. Fowler, Unsu Jung, Ronald E. Gress, Bruce Levine, Carl June